Current Report Filing (8-k)
August 20 2020 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
August 20, 2020
Date of Report (date of earliest event reported)
_________________
OpGen, Inc.
(Exact name of Registrant as specified in
its charter)
_________________
Delaware
(State or other jurisdiction of incorporation
or organization)
|
|
001-37367
(Commission
File Number)
|
|
06-1614015
(I.R.S. Employer
Identification Number)
|
708 Quince Orchard Road, Suite 205
Gaithersburg, MD 20878
(Address of principal executive offices)
(240) 813-1260
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
OPGN
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 7.01 Regulation FD Disclosure.
On August 20, 2020, OpGen, Inc. updated its corporate
presentation, which it made available on its website. A copy of the presentation is furnished as Exhibit 99.1 to this report.
Item 8.01 Other Events.
On August 20, 2020, OpGen, Inc. issued a press release announcing
its subsidiary, Curetis GmbH, has obtained the CE mark certification in the European Union for its SARS-CoV-2 test kit that
tests for the detection of SARS-CoV-2, the virus that causes COVID-19. A copy of the
press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The information included in Item 7.01 of this report
and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: August 20, 2020
|
|
OpGen, Inc.
|
|
|
|
|
|
|
By:
|
|
/s/ Timothy C. Dec
|
|
|
|
|
Name:
|
|
Timothy C. Dec
|
|
|
|
|
Title:
|
|
Chief Financial Officer
|
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024